-
-
-
-
-
-
-
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
-
-
-
-
-
-
-
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
-
-
-
-
-
-
-
Harrow Launches Harrow Access for All (HAFA)
-
-
-
-
-
-
-
Harrow Health (HROW) Acquires U.S. Commercial Rights to BYQLOVI
-
-
-
-
-
-
-
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
-
-
-
-
-
-
-
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
-
-
-
-
-
-
-
Harrow Relaunches TRIESENCE®
-
1,160,153 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

